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ABSTRACT
Introduction: Diabetes is a chronic condition
associated with many long-term complications. People
with diabetes need to actively manage their condition,
which can be complex. In consultations with healthcare
professionals, patients receive advice about their
diabetes but do not always discuss things which
concern them, perhaps because of the perceived
limited time or embarrassment. We want to test a
‘preconsultation’ intervention in which the patient is
supported by a healthcare assistant to complete a web-
based intervention aimed at producing an agenda to
help them identify important areas for discussion in
the consultation. Use of this agenda may enable the
patient to play a more active role in that consultation
and consequently become more confident, and hence
more successful, in managing their condition.
Methods and analysis: In this pilot randomised
controlled trial, 120 people with diabetes will be
randomised with equal allocation to receive the
intervention or usual clinical care. The primary outcome
is reduction in glycosylated haemoglobin(HbA1c).
Secondary outcomes are patient-reported
communication, enablement, self-care activity, diabetes-
dependent quality of life, empowerment, satisfaction,
health-related quality of life and resource use. The aim
of the pilot study was to estimate parameters to inform
the design of the definitive trial. Follow-up on
quantitative outcomes will be at 3 and 6 months.
A nested qualitative study will collect data on the
patients’ experiences of producing an agenda. Resource
use data and medication use will also be collected via a
review of medical records for a sample of participants.
Ethics and dissemination: Approval was granted by
the NHS Research Ethics Committee North West—
Preston (13/NW/0123). Dissemination will include
publication of quantitative and qualitative findings, and
experience of public involvement in peer-reviewed
journals. Results will also be disseminated to trial
participants via workshops led by lay coapplicants.
Trial Registration: ISRCTN75070242.
ARTICLE SUMMARY
Article focus
▪ This paper describes a protocol for a pilot
randomised controlled trial of a preconsultation
web-based intervention to enable patients with
diabetes to produce their own agenda for a con-
sultation with their diabetologist.
Key messages
▪ A preconsultation intervention in which the
patient is supported by a healthcare sssistant to
complete a web-based intervention will facilitate
the production of ‘their agenda’ to help them
identify important areas for discussion in the
consultation.
▪ Combining trial as well as qualitative research
methods ensures that the ‘active ingredients’ of
the intervention are identified and explored,
which will enable estimate parameters to inform
the design of a definitive trial.
▪ Involving patients as collaborators ensures that
this research deals explicitly with patients’ infor-
mation needs, thus increasing the probability of
the DIAT intervention being taken up in practice.
Strengths and limitations of this study
▪ This study addresses areas identified as requir-
ing more research in the 2013 Cochrane review
of computer-based diabetes self-management
interventions for adults with type 2 diabetes,
which identified that interventions may have a
small effect on blood glucose, but no benefits to
cognitive, behavioural or emotional outcomes.
The intervention is grounded in real-world
patient experience, and pragmatically designed to
be scaled up for a definitive trial and use in prac-
tice, but a potential limitation is that the
follow-up period may not be long enough to
demonstrate a reduction in glycosylated
haemoglobin.
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INTRODUCTION
Diabetes will affect an estimated 439 million people glo-
bally by 2030, with an estimated 2.5 million in the UK.1
Diabetes is a chronic disease, associated with a number
of serious complications, and the costs of treating a
person with diabetes rise by 60–90% as vascular pro-
blems progress.2 Up to 80% of the National Health
Service’s (NHS) £9.8 billion annual UK expenditure on
diabetes is spent on treating complications.3
Diabetes is largely monitored and managed by patients
themselves.4 Self-management is complex, involving,
among other things, self-monitoring, behavioural
change, medication management and a rigorous lifestyle
regimen. Advice from professionals is vital to self-
management, improving patients’ ability to cope with
their illness. Effective consultations are associated with
empowerment, positive behaviour change and improved
diabetes outcomes.5–9 However, consultations with diabe-
tologists are infrequent and patients often do not take
full advantage of their time with their clinician.10 They
may feel embarrassed, rushed or simply have forgotten
some of the urgent problems they encountered since
their previous consultation. Patients with types 1 and 2
diabetes attending two diabetes centres in England per-
ceived that they were not commonly questioned about
sensitive aspects of their condition, such as erectile dys-
function and gastroparesis.11 A UK service evaluation
identiﬁed that health professionals, including diabetolo-
gists, felt competent in identifying patients’ psychological
issues but less knowledgeable and skilled in handling
them.12 Thus, methods to improve the quality of consul-
tations in terms of the ability of the patient to discuss
issues that concern them, understand information and
remember and follow advice are consistently sought.
A systematic review found that the most common
methods used to improve the quality of consultations are
question checklists and patient coaching delivered imme-
diately before consultations, and that information-
seeking behaviour and patient satisfaction were most
improved by combining coaching with written material.13
Greenﬁeld et al’s14 study, using a review of medical
records, a treatment algorithm and a behavioural change
strategy, improved patient participation in the consult-
ation and glycaemic control. A recent systematic review of
computer-based diabetes self-management interventions
for adults with type 2 diabetes identiﬁed 16 randomised
controlled trials, but was unable to distinguish between
those that were set in primary care, outpatients or com-
munity settings.15 The reviewers concluded that diabetes
self-management interventions may have a small effect
on blood glucose, with mobile ‘phone-based interven-
tions having a greater impact than computer-based inter-
ventions, and no evidence of beneﬁts to cognitive,
behavioural or emotional outcomes’. In conclusion, they
were unable to discern the active ingredients or optimal
‘dose’ of the interventions.
A relatively inexpensive intervention has been devel-
oped by Cegala et al, evolving from an instruction
booklet, to booklet plus coaching, to a web-based train-
ing module (http://patcom.jcomm.ohio-state.edu/).
Cegala et al16 identiﬁed that effective communication
involves patients: presenting detailed information about
how they are feeling; asking questions if desired informa-
tion is not provided; checking understanding of informa-
tion that is given to them and expressing any concerns
about the recommended treatment. This ‘PACE’ system
has shown promise in oncology,17 has an outcome
measure for communication18 and can easily be tailored
for use by people with diabetes.
The intervention has been designed to facilitate the
articulation of patients’ often unvoiced agendas16 18–25
which arise from their continual efforts to manage their
conditions.26 27 Discussion of these agendas enables
patients to manage their condition more effectively,7 28–30
which includes better adherence.31 32
The PACE intervention has been modiﬁed speciﬁcally
for diabetes (as PACE-diabetes or PACE-D) by the DIAT
Project Team. PACE-D is a web-based tool, designed to
be completed by a patient before a clinic appointment.
In this study, the appointment is with a consultant
diabetologist.
A trained healthcare assistant (HCA) will facilitate the
use of the PACE-D tool, with the aim of assisting patients
to identify the things that they wish to discuss with the
diabetologist (ie, their ‘agenda’) in the clinical consult-
ation. The intervention takes approximately 20 min to
complete, and consists of a series of open and closed
questions, prompts and a list of possible concerns that
people with diabetes have identiﬁed (eg, ‘increased
thirst’ or ‘depression’). On completion, a concise
agenda will automatically be produced, which the
patient will take into their consultation with a diabetolo-
gist, and which may be used subsequently (ie, in discus-
sions with the general practitioner (GP) or practice
nurse, and to guide self-management).
PACE-D aims to enable patients to identify their
agenda for discussion with the diabetologist, improving
communication and empowering patients to be more
proactive at managing their diabetes, potentially leading
to improved clinical and quality-of-life outcomes. The
intervention appears to be a simple and relatively inex-
pensive tool but requires a rigorous test of its efﬁcacy
and cost-effectiveness. Piloting the PACE-D intervention
and agenda with people with diabetes could provide
improvements in communication, blood glucose man-
agement, enablement, self-care, medication use and
quality of life, with little impact on cost or clinic time.
We will measure enablement and patient perceptions of
the effectiveness of the consultation, which are per-
ceived as crucial to effective diabetes control.28
The aim of this pilot study was to obtain the necessary
information for the planning of a future deﬁnitive trial
to assess the clinical and cost-effectiveness of a preclinic
intervention speciﬁcally for diabetes.
The primary objective of this pilot study was to test the
feasibility of running a randomised controlled trial of a
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preconsultation web-based intervention to improve the
care quality and clinical outcomes of people with
diabetes.
The secondary objectives were to determine:
▸ The likely success of recruitment strategies.
▸ The acceptability of the research plan to proposed
participants and allowance for the estimation of likely
participation and attrition rates.
▸ The data that will be useful for estimating the
required sample size for a full trial.
▸ The training requirements of those clinic staff tasked
with implementing the intervention.
▸ Resource use, for example, the use of staff, required
to provide the intervention and usual care.
▸ A preliminary estimate of the cost of the intervention.
▸ The validity and responsiveness of quality-of-life
outcome measures in the patient group (including
generic preference-based measures).
▸ The practicality and accuracy of using alternative
methods of data collection for service and resource
use (ie, patient report/review of medical records).
Patient and public involvement
Patient and public involvement (PPI) is fundamental to all
aspects of this research. The research question was gener-
ated from a research prioritisation exercise, undertaken by
the National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health Research
and Care in the South West Peninsula (PenCLAHRC) with
active involvement from the Peninsula Patient and Public
Involvement Group (PenPIG).
People with diabetes identiﬁed the research topic and
suggested that outpatient clinic appointments are pres-
sured times, where health professionals can overlook
issues that are worrying patients or where patients can
feel inhibited from voicing their concerns. The same
topic was identiﬁed by a diabetes specialist nurse (DSN)
at a comparable professional workshop.
A project team was convened and a scoping exercise
undertaken to assess what is known about the problem,
and members of PenPIG discussed the existing research
and perceptions of current and desired future clinic
consultations. Two members of PenPIG who have dia-
betes joined the research team as coapplicants on this
proposal. They also have representative roles within the
local Diabetes Research Network and Devon Diabetes
Service Strategy Implementation Group. Supported by a
designated PPI Research Fellow, these two coapplicants
have cowritten the study documentation and will assist in
the analysis of the data and the dissemination of the
research results to lay and professional audiences. They
are members of the project management team and will
assist in training HCAs.
If the ﬁndings of the pilot indicate feasibility, there
will be patient and public coapplicants on the full trial
proposal, which will be submitted to an appropriate
source of funding. Members of the public involved in
this pilot will be paid travel expenses and receive a
payment in recognition of their contribution to the
research.
METHODS
Trial design
The pilot trial is a pragmatic pilot randomised con-
trolled trial. The outcomes were chosen and the inter-
vention designed during the development phase of the
study (see Discussion section; ﬁgure 1).
Participants and study setting
The pilot trial will recruit 120 patients attending diabetes
outpatient clinics at two hospitals in Devon, south-west
England, which treat people from urban and rural set-
tings. In 2010/2011, these two diabetes centres under-
took approximately 9000 new appointments and 12 000
follow-up appointments. People with a range of diabetes
complications and comorbidities will be included in the
pilot, and the experiences gained will inform the inclu-
sion and exclusion criteria of the larger trial. Although
the intervention might potentially have beneﬁt for all
consultations (including those in primary care), the
beneﬁt is likely to be greater in secondary care where typ-
ically more issues and problems are discussed. Eligible
patients are adults with type 1 or 2 diabetes mellitus who
are due to attend outpatient appointments with a diabe-
tologist. Participants are aged 18 or over and have basic
spoken or written English (to complete outcome mea-
sures). Women with pre-existing or gestational diabetes
and people receiving insulin pump therapy are excluded.
Recruitment of patients
The study sample comprises people with diabetes who
are due to attend a general diabetes clinic appointment
at the Macleod Diabetes and Endocrine Centre at the
Royal Devon and Exeter Hospital, Exeter, or the Medical
Outpatients Department at Derriford Hospital,
Plymouth. Potential participants will be identiﬁed from
the clinic lists of participating consultant diabetologists
by a research nurse at each location. Patients who express
an interest in participating in the trial will be sent an
information sheet. A research nurse will telephone each
potential participant after a minimum of 1 week, discuss
any questions that the patient may have and establish if
they are willing to participate. The nurse will then send a
consent form and baseline questionnaires to those willing
to take part. Following receipt of informed written
consent and the completed baseline questionnaires, par-
ticipants will be randomised to receive either the inter-
vention or usual care (control), as detailed below.
Intervention
In a 20 min session immediately preceding the clinic
appointment, a trained HCA will help the patient to
complete the PACE-D tool (the aim being for the
patient to identify and produce their own agenda for
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the consultation). After the intervention, the patient will
proceed to the clinical consultation, in which the
printed output from the PACE-D intervention will act as
an agenda for the consultation. Owing to the nature of
the intervention and the production of an agenda, it
will not be possible to blind health professionals or
patients to trial allocation. With consent, 10 participants
across the two sites will be audio-recorded as they use
the PACE-D tool, for qualitative analysis.
Control
This comprises clinical care normally given by the diabe-
tologist in outpatient clinics.
Outcomes
Primary outcome measure
The primary outcome measure is glycosylated haemoglo-
bin (HbA1c),33 a measure of glycaemic control. HbA1c
levels will be measured within 4 weeks of each assess-
ment (ie, at baseline, 3 and 6 months), and will be retro-
spectively obtained from participants’ medical records.
Secondary outcome measures
Secondary outcome measures (patient self-reported
rating scales) will be measured at all three time points.
The rating scales will be sent to all participants with
instructions for completion and a prepaid return enve-
lope. In addition, participants will be asked to document
their current medication at each time point, as well as
the number and type of contacts with primary and sec-
ondary care practitioners during the study. Those in the
treatment arm will also be asked at 6 months about their
experience of using the PACE-D tool and the utility of
producing ‘their agenda’.
Patient self-reported outcome measures:
Figure 1 DIAT trial schedule.
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Audit of Diabetes-Dependent Quality of Life-19 (ADDQoL):
Developed to measure an individual’s perception of
the impact of diabetes on their quality of life,34 this
tool has 2 overview items and 19 individual domains
(eg, working life, holidays, physical appearance, etc).
For each domain, the respondent reports the impact of
diabetes on their quality of life (on a 5-point scale,
scored from −3 to 1 with higher scores indicating a
greater impact) and the importance of the domain (on
a 4-point scale score from 0 to 3 with higher scores
indicating greater importance). The quality-of-life
score for each domain is calculated by taking the
product of the impact and importance scores with
scores ranging from –9 (maximum negative impact of
diabetes) to +3 (maximum positive impact of dia-
betes). The average weighted impact score is calculated
as the mean across the domain scores. The Patient
Report of Outcomes Measure Group, Oxford35 recom-
mends the use of ADDQoL as their preferred diabetes-
speciﬁc measure.
Client services receipt inventory: Originally developed for
collecting cost-related information for people with
mental health problems over a given period (usually
the past 6 or 12 months),36 this is a long-established
and widely adapted questionnaire. It collects retro-
spective information about the interviewee’s use of
health and social care services, home and employment
situation, as well as income and beneﬁts. We will pilot
a simpliﬁed version of this questionnaire, tailored for
diabetes and capturing resource use over a 3-month
period, for intended use in the main trial.
Diabetes empowerment scale-short form (DES): This scale
was developed in the USA to measure diabetes-related
psychosocial self-efﬁcacy.37 38 This eight-item scale,
derived from a behaviour change model, employs a
ﬁve-point Likert scale (strongly disagree (1) to strongly
agree (5)). An overall score for DES is calculated by
taking the mean of the item scores.
Diabetes self-care activity measure: This 11-item instru-
ment is a self-reported questionnaire of diabetes self-
management which includes ﬁve aspects (activities) of
the diabetes regimen.39 40 Questions for general diet
(two items), speciﬁc diet (two items), exercise (two
items), blood glucose testing (two items) and foot
care (two items) use an eight-point Likert scale (from
0 to 7) to record the number of days in the past week
that the activity was undertaken. The overall score for
each activity is calculated as the mean of the two
items. Smoking (during the past 7 days) is recorded as
yes or no, with smokers additionally reporting the
number of cigarettes smoked on an average day.
Diabetes treatment satisfaction questionnaire—status (status,
DTSQ(S)) and change versions: DTSQ(S) was developed
to measure patient satisfaction with diabetes treat-
ment.41 42 DTSQ(S) consists of six items to assess treat-
ment satisfaction and two items to capture patient
perceived hypoglycaemia/hyperglycaemia. The DTSQ
(S) items are scored on a Likert scale from 0 to 6 (0=very
dissatisﬁed, 6=very satisﬁed). A total score is created as the
sum of scores across the treatment satisfaction items
(possible score from 0 to 36). In response to concerns
about ceiling effects, where high baseline scores provide
little opportunity to register change at follow-up,
the authors produced the DTSQ ‘change’ version
(DTSQ(C)), which contains the same items, but asks
patients to consider their satisfaction with current treat-
ment compared with their previous treatment.43 DTSQ
(C) items are scored on a scale from −3 to 3 (−3=less sat-
isﬁed now, 3=more satisﬁed now, with a midpoint of 0
reﬂecting no change). The total score is again calcu-
lated by summing the scores on the treatment satisfac-
tion items, with the range of possible values from −18 to
18. Both versions will be used in order to capture initial
perceptions and any change at follow-up.
EuroQoL (EQ-5D-5 L): The original EQ-5D is a generic
measure for valuing and describing health. It deﬁnes
health in terms of: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression and uses a
three-point Likert scale (no problem, some problem,
extreme problem44). EQ-5D health states, deﬁned by the
EQ-5D descriptive system, may be converted into a
single summary index by applying a formula that
essentially attaches values (also called weights) to each
of the levels in each dimension. The Patient Report of
Outcomes Measure Group, Oxford35 recommends the
use of EQ5D as their preferred generic measure in
combination with a disease-speciﬁc instrument.
However, this instrument has also been found to suffer
from ceiling effects, and a ﬁve-level version has been
developed (EQ-5D-5 L), which uses a ﬁve-point Likert
scale (no problem, slight problem, moderate problem, severe
problem, extreme problem) and has demonstrated
increased reliability and sensitivity.45
Patient enablement instrument (PEI): Developed to
measure patient enablement after a consultation with
a physician, PEI contains six items with a four-point
Likert scale: not applicable/same or less (0); better/more
(1); much better/much more (2).46 The total score is the
sum of scores across the items (possible range of
scores is 0 to a maximum score of 12). Haughney
et al47 have subsequently modiﬁed the opening state-
ment to capture perspectives on treatment speciﬁcally,
and this version will be used.
Patient report of communication: Developed to measure
communication in conjunction with the PACE tool,
this instrument comprises 11 questions about per-
ceived communication, with two items for each of the
four PACE skills, two additional items for the patient’s
ability to state their preferences and a global item
about the consultation.18 It uses a 5-point Likert scale
that captures aspects of doctor–patient communica-
tion as never (1), not very often (2), sometimes (3), usually
(4) and always (5). Mean scores will be calculated for
each PACE skill and across all 11 items. This instru-
ment has been shown to be reliable in patients with
cancer and those undergoing surgery.18
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Participant timeline
A brief explanation of the participant’s timeline is
shown in (ﬁgure 2).
Sample size
As this is a pilot study, comparison of the outcomes
between the trial arms is not a major objective and the
study is not powered to do this. We aim to recruit 120
patients, 60 at each site. At least six clinic ‘sessions’ (ie,
the period of time in which a clinic is held within the
outpatient department, usually in the morning or after-
noon, when 8–15 patients are seen by their consultant)
at each site will be required.
An objective of the pilot study is to estimate the SD for
continuous outcomes to be used in the deﬁnitive trial as
this will facilitate the sample size calculation for that
study. We anticipate that at least half of the participants
(ie, 60) will provide the follow-up data at 6 months. Sixty
patients are sufﬁcient to estimate an SD to within 22%
of its true value based on the upper bound of the
95% CI.
The study will also estimate the percentage of eligible
participants that participate and the percentage of parti-
cipants that are successfully followed up. If the true per-
centage of participants that provide follow-up data at
6 months is 50%, this study will be able to estimate this
with a margin of error of ±13%, based on a 95% CI,
assuming that participants from a given clinic session are
no more likely to drop out than those from another
session.
Randomisation
An independent statistician based at the Peninsula
Clinical Trials Unit (PenCTU) will generate the random-
isation list, using computer-generated random numbers.
Randomisation will be stratiﬁed by clinic session.
Randomisation will be achieved by means of an auto-
mated web-based system created by a PenCTU data pro-
grammer in conjunction with the independent
statistician and accessed by a separate member of the
PenCTU staff on receipt of the completed consent form.
Consenting participants will be allocated with equal
probability to receive PACE-D or usual clinical care,
using randomly permuted blocks of varying size to gen-
erate the allocation sequence and achieve balance in the
numbers of participants allocated to each group.
Following randomisation, PenCTU will notify partici-
pants by standard letter about the arrival time for their
clinic appointment. Those in the intervention arm will
be notiﬁed that they are required to arrive 30 min early,
while those in the control arm will be notiﬁed that they
are not required to arrive early.
Statistical methods
The main aim of this pilot study was to estimate para-
meters that will ultimately inform the design of the main
trial. The participation rate will be calculated as the per-
centage of eligible participants that are randomised,
with 95% CIs. The loss to follow-up rate will be reported
at 3 and 6 months with 95% CIs. SD will be reported
with 95% CIs for the primary outcome. Other para-
meters to be reported include mean duration of the
clinic conversation in each trial arm.
In ancillary analyses, baseline characteristics will be
reported using percentages for categorical data, and
means and SDs (or medians and IQRs) for quantitative
data. The trial arms will be compared at 3 and 6 months
using the t test for quantitative outcomes and the χ² test
for binary outcomes. Linear and logistic regression,
respectively, will be used to adjust comparisons for base-
line scores on the outcome. There will be no interim
analyses, and neither will stopping rules be applied.
Missing data will not be imputed.
Qualitative methods
Ten intervention sessions will be audio-recorded with
the participants’ consent, in order to explore howFigure 2 Flow of participants.
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participants utilise the PACE-D intervention and the
amount of assistance that they require from HCA in
order to complete their agenda form.
In addition, approximately 30 clinical consultations
across both trial arms and study sites will be audio-
recorded, with the consent of both the participants and
their diabetologist. Maximum variance sampling will be
used so that any impact of variables of interest (ie,
patient age, clinician grade or clinic site) can be
explored.
Recording consultations is crucial to understanding
the mechanism that underlies the impact of the produc-
tion of an agenda on the clinical consultation, and its
subsequent utilisation in practice, when compared with
usual care. Hence, we will report on the ﬁdelity of the
intervention, content of the consultation, context for
the use of the agenda and any impact on the
consultation.
Semistructured interviews will also be conducted with
a sample of 30 participants across trial arms and
research sites, after participation in the trial has been
completed and in order to examine aspects of interven-
tion and participants’ experiences of diabetes consulta-
tions in more depth.48 With the participants’ consent,
these interviews will be audio-recorded and will explore:
participants’ experience of diabetes and clinical consul-
tations; raising concerns with health professionals in
primary and secondary care; participants’ experience of
either usual care or intervention and trial participation.
For the semistructured interviews, participants in both
trial arms will be purposefully sampled to include those
with type 1 or 2 diabetes, new and existing patients, and
people with different ages/genders/socioeconomic
backgrounds and, where possible, different comorbid-
ities, following a maximum variation sampling strategy.49
It is necessary to include interviews with participants in
the usual care arm of the trial to explore how patients
normally voice their agendas during diabetes consulta-
tions, and with what consequences. The interviews will
take place after the ﬁnal follow-up at 6 months, to avoid
any inﬂuence of the interview on these measures.
Interviews will be conducted at a location that is con-
venient to the participant.
A topic guide will be used, which has been developed
with involvement from the PPI coapplicants, to ensure
that the primary issues are covered, while allowing ﬂexi-
bility for new issues to emerge from each interview.
Interviews will be digitally recorded, fully transcribed
and anonymised to protect conﬁdentiality.
In addition to the interviews with participants,
approximately 10 interviews with health professionals
(eg, HCAs, research nurses and diabetologists) involved
in the study at each research site will be conducted near
the end of the trial. They will explore the professionals’
views about the intervention and issues around imple-
mentation. A ﬂexible topic guide will be employed and
these interviews will explore: professionals’ experience
of diabetes and clinical consultations; addressing
patients’ concerns in secondary care; professionals’
experience of usual care and the intervention and trial
participation.
The audio-recordings from the consultations and
interviews will be transcribed and read in detail by team
members who are experienced in qualitative research
methods and a list of common themes and concepts
drawn up.26 Data collection and analysis will be literative
and ongoing, with the coding frame reﬁned as new
themes and categories are identiﬁed from subsequent
interviews.50 The qualitative data will be managed using
Nvivo software.
Cost-effectiveness methods
An economic evaluation will not be conducted as part of
this pilot study. However, data will be collected to inform
the design of the economic evaluation alongside the
planned deﬁnitive trial, by: comprehensively estimating
the range of care resource use and cost impacts related
to the intervention (ie, potential costs of implementa-
tion using HCA or research nurses or DSNs or other
modes of delivery) and its expected outcomes; reﬁning
and justifying the choices of outcome measures for
health-related quality of life and testing the practicality
and validity of methods for collecting patient-reported
resource/service use; and providing some preliminary
estimates of different parameters and their variances.
Dissemination
Dissemination of the results and projected outputs will
be appropriate to that of a pilot study, and the key
output will be an application to an appropriate funder
for a deﬁnitive trial of the intervention. As the research
question was generated through the PPI Group, and
service users are integral to the research team, the
results of the study will be of particular interest to those
who use diabetic services. The PPI coapplicants with
other members of the research team will disseminate
the results of this pilot to the trial participants, via two
workshops, which will be conducted at neutral locations
towards the end of the study.
The results from the pilot will be more widely dissemi-
nated in order to share our experiences and to generate
enthusiasm for the future deﬁnitive trial. We will inform
people with diabetes through articles in lay health maga-
zines, electronic forums and presentations. We will
inform clinicians and health-service managers through
submissions to appropriate journals and presentations at
suitable conferences.
Results from the future deﬁnitive trial would be disse-
minated widely through a variety of media, including
peer-reviewed journal articles and conference presenta-
tions, with an emphasis on reaching NHS policymakers
and commissioners, health professionals and service
users.
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DISCUSSION
During the development phase of the research, three
key methodological aspects were discussed.
The research team has purposely chosen to trial the
PACE-D (intervention) in secondary care—a decision
which was much debated during the study development
phase. Discussions included people with diabetes (both
types 1 and 2, including those who have experience of
consultations with diabetologists in the hospital out-
patient setting), GPs, diabetologists, DSNs, practice
nurses and lay and professional members of the
Diabetes Research Network and Primary Care Network.
Following these lengthy discussions, a decision was made
to sample new and existing patients attending clinic
appointments with six diabetologists at two different hos-
pitals, as it is believed that these people may have a par-
ticular set of concerns. If the intervention is successful
in this population, we may consider undertaking future
research with the intervention in primary care settings,
where patients may have a different set of concerns.
The potential for contamination between the trial
arms resulting from the use of individual patient ran-
domisation was debated by the research team, and a
number of alternative randomisation strategies were con-
sidered, including cluster randomisation of clinics, con-
sultants or sites. The research team reached a consensus
that contamination is unlikely in this context, given that
the active ingredient of the intervention is use of the
PACE-D tool, and therefore decided to use individual
randomisation.
People with diabetes identiﬁed the research topic and
requested that the intervention (PACE-D) should be
facilitated by a DSN. However, while the study was being
designed and discussions with local NHS partners were
undertaken, it was apparent that DSNs are increasingly
time pressured. A pragmatic decision was therefore
made by the research team, including lay representa-
tives, that the trial intervention should be facilitated by a
number of HCAs routinely present at general outpatient
diabetes clinics, and who will be trained in study proce-
dures by a DSN coapplicant. It is thought that this will
provide a valid insight into how the intervention would
work in a future trial and in the ‘real world’ clinical
setting.
CONCLUSION
People with diabetes need to actively monitor and
manage their condition; however, they are not always
able to discuss things which concern them at clinical
consultations with their diabetologist. Guidelines in the
UK emphasise the importance of more actively involving
people with diabetes in the consultation process and
ongoing management of their condition. The DIAT
study aims to inform best practice in this area by evaluat-
ing an intervention to assist patients to produce an
agenda for their consultation. We think that this may
enable patients to play a more active role in that
consultation and subsequently make them more
enabled, and hence successful at managing their
condition.
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